Abbonarsi

Randomized trial comparing the 22-gauge aspiration and 22-gauge biopsy needles for EUS-guided sampling of solid pancreatic mass lesions - 20/07/12

Doi : 10.1016/j.gie.2012.03.1392 
Ji Young Bang, MBBS, MPH 1, Shantel Hebert-Magee, MD 2, Jessica Trevino, MD 1, Jayapal Ramesh, MD 1, Shyam Varadarajulu, MD 1,
1 Division of Gastroenterology-Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA 
2 Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA 

Reprint requests: Shyam Varadarajulu, MD, Director of Endoscopy, Basil I. Hirschowitz Endoscopic Center of Excellence, University of Alabama at Birmingham, JT 664, 619-19th Street S, Birmingham, AL 35294-0007

Riassunto

Background

To overcome limitations of cytology, biopsy needles have been developed to procure histologic samples during EUS.

Objective

To compare 22-gauge (G) FNA and 22G biopsy needles (FNB) for EUS-guided sampling of solid pancreatic masses.

Design

Randomized trial.

Setting

Tertiary-care medical center.

Patients

This study involved 56 patients with solid pancreatic masses.

Intervention

Sampling of pancreatic masses by using 22G FNA or 22G FNB devices.

Main Outcome Measurements

Compare the median number of passes required to establish the diagnosis, diagnostic sufficiency, technical performance, complication rates, procurement of the histologic core, and quality of the histologic specimen.

Results

A total of 28 patients were randomized to the FNA group and 28 to the FNB group. There was no significant difference in median number of passes required to establish the diagnosis (1 [interquartile range 1-2.5] vs 1 [interquartile range 1-1]; P = .21), rates of diagnostic sufficiency (100% vs 89.3%; P = .24), technical failure (0 vs 3.6%; P = 1.0), or complications (3.6% for both) between FNA and FNB needles, respectively. Patients in whom diagnosis was established in passes 1, 2, and 3 were 64.3% versus 67.9%, 10.7% versus 17.9%, and 25% versus 3.6%, respectively, for FNA and FNB cohorts. There was no significant difference in procurement of the histologic core (100% vs 83.3%; P = .26) or the presence of diagnostic histologic specimens (66.7% vs 80%; P = .66) between FNA and FNB cohorts, respectively.

Limitations

Only pancreatic masses were evaluated.

Conclusion

Diagnostic sufficiency, technical performance, and safety profiles of FNA and FNB needles are comparable. There was no significant difference in yield or quality of the histologic core between the 2 needle types. (Clinical trial registration number: NCT01394159.)

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : EUS-FNA, FNB, HBSS, TNB


Mappa


 DISCLOSURE: S. Varadarajulu is a consultant for Boston Scientific. No other financial relationships relevant to this publication were disclosed.
 See CME section; p. 396.


© 2012  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 76 - N° 2

P. 321-327 - agosto 2012 Ritorno al numero
Articolo precedente Articolo precedente
  • Diagnostic significance of a dilated orifice of the duodenal papilla in intraductal papillary mucinous neoplasm of the pancreas
  • Teppei Aso, Takao Ohtsuka, Noboru Ideno, Hiroshi Kono, Yosuke Nagayoshi, Yasuhisa Mori, Kennoki Ohuchida, Junji Ueda, Shunnichi Takahata, Katsuya Morimatsu, Shinichi Aishima, Hisato Igarashi, Tetsuhide Ito, Kousei Ishigami, Kazuhiro Mizumoto, Masao Tanaka
| Articolo seguente Articolo seguente
  • Diagnostic yield of malignancy during EUS-guided FNA of solid lesions with and without a stylet: a prospective, single blind, randomized, controlled trial
  • Sachin Wani, Dayna Early, Julie Kunkel, Ann Leathersich, Christine E. Hovis, Thomas G. Hollander, Cara Kohlmeier, Cynthia Zelenka, Riad Azar, Steven Edmundowicz, Brian Collins, Jingxia Liu, Matthew Hall, Daniel Mullady

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.